ArticleESMO open2022

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.

B Kiesewetter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.